Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型
基本信息
- 批准号:10685383
- 负责人:
- 金额:$ 54.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-21 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AerosolsAffinityAnimalsAttenuated VaccinesBacteriaBacterial InfectionsBiochemicalBioterrorismBurkholderia pseudomalleiCellsChemicalsClassificationComplexContractsCryo-electron tomographyCryoelectron MicroscopyCuesCytosolDevelopmentDiseaseDoseEarly identificationElectronsEndowmentEscherichia coliEukaryotic CellExhibitsFederal GovernmentFoundationsFrancisellaFrancisella tularensisFree EnergyFreezingFutureGenesGeneticGoalsGram-Negative BacteriaHomologous GeneHumanHybridsIn SituInfectionInfection preventionInjectionsKnowledgeLabelLife StyleMacrophageMass Spectrum AnalysisMediatingMembraneMethodsModelingMolecular ConformationMolecular StructureMorbidity - disease rateMutagenesisPathogenesisPathogenicityPathogenicity IslandPhagosomesProcessProkaryotic CellsProteinsProteomicsRestRoleRotationSequence HomologyStructureSystemTechnologyTestingToxinTubeTularemiaVibrio choleraeVirulenceVirulentWestern Blottingcombatcrosslinkdesigngenetic manipulationhuman diseasehuman pathogenmortalitynanomachineparticlepathogenic bacteriapreventprotein complexreconstruction
项目摘要
Project Summary/Abstract
Francisella tularensis is a bacterium that causes tularemia, a disease which, when in its pneumonic form, can
be fatal even with appropriate treatment. Due to its low infectious dose, ease of spread by aerosol, and high
virulence, F. tularensis is classified as a Tier 1 Select Agent by the U.S. federal government. This R01 project
builds on our earlier identification (by contact PI Horwitz's group) of the Francisella Type VI Secretion System
(T6SS) and our subsequent determination (by Horwitz's and MPI Zhou's group) of the first atomic models of its
sheath and its uniquely endowed central spike complex through cryo electron microscopy (cryoEM). T6SSs are
large, complex, multi-protein nanomachines that Gram-negative bacteria use to sense environmental cues and
deliver toxins into other bacteria or into eukaryotic hosts; in Francisella, they mediate phagosome escape and
intracytoplasmic replication. They are important virulence determinants, present in 25% of Gram-negative
bacteria and in an even higher percentage of those that are human pathogens. However, without knowing
T6SS composition and structure, we cannot fully understand its mechanisms of pathogenesis nor effectively
design countermeasures against a myriad of bacterial diseases. The T6SS of Francisella is both significant
and attractive to study because of the high infectivity and lethality of Francisella species and its relative
simplicity compared with other T6SSs. However, significant knowledge gaps remain, including the following:
(1) an atomic model of the structure of the pre-contraction outer sheath; (2) the composition and an atomic
model of the baseplate and membrane complex; and (3) the composition of the Francisella central spike and
secreted effector protein complex and an atomic model of its interaction with the sheath, baseplate, and
membrane complex in the pre-contraction state and during the contraction process.
To fill these gaps, we propose to carry out three major structure-function studies on T6SS using
Francisella novicida [and its closely related F. tularensis live vaccine strain (LVS)] as a model. First, we shall
obtain the atomic model of the sheath and tube complex in purified T6SS in its pre-contraction state with
cryoEM, and elucidate the energetics and mechanism of T6SS contraction by structural comparison with the
contracted sheath and structure-guided mutagenesis. Second, using proximity labeling, crosslinking, affinity
pull-down, immunoblotting, proteomics, and bacterial 2-hybrid analyses, we shall determine the composition
and protein interactions of the baseplate and membrane core complex. This information will be used in
conjunction with cryo electron tomography of T6SS-containing mini-cells to determine the composition and
structure of the T6SS baseplate and membrane complex in their pre- and post-contraction states. Third, we
shall determine the composition and structure of the Francisella T6SS central spike and secreted effector
complex. The results will form the foundation for future function studies and the development of new strategies
for treating and preventing diseases caused by the numerous important pathogenic bacteria that have a T6SS.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARCUS AARON HORWITZ其他文献
MARCUS AARON HORWITZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARCUS AARON HORWITZ', 18)}}的其他基金
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
基于精确控制的复制限制结核分枝杆菌,开发出比卡介苗更安全、更有效的新型结核疫苗,该疫苗经过精心设计,可实现最佳的体内生长和清除
- 批准号:
10115911 - 财政年份:2021
- 资助金额:
$ 54.97万 - 项目类别:
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
基于精确控制的复制限制结核分枝杆菌,开发出比卡介苗更安全、更有效的新型结核疫苗,该疫苗经过精心设计,可实现最佳的体内生长和清除
- 批准号:
10372028 - 财政年份:2021
- 资助金额:
$ 54.97万 - 项目类别:
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
基于精确控制的复制限制结核分枝杆菌,开发出比卡介苗更安全、更有效的新型结核疫苗,该疫苗经过精心设计,可实现最佳的体内生长和清除
- 批准号:
10570976 - 财政年份:2021
- 资助金额:
$ 54.97万 - 项目类别:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型
- 批准号:
10462669 - 财政年份:2020
- 资助金额:
$ 54.97万 - 项目类别:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型
- 批准号:
10120412 - 财政年份:2020
- 资助金额:
$ 54.97万 - 项目类别:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型
- 批准号:
10267736 - 财政年份:2020
- 资助金额:
$ 54.97万 - 项目类别:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
使用 LVS dcapB 载体平台开发安全有效的类鼻疽疫苗
- 批准号:
10837445 - 财政年份:2019
- 资助金额:
$ 54.97万 - 项目类别:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
使用 LVS dcapB 载体平台开发安全有效的类鼻疽疫苗
- 批准号:
10308602 - 财政年份:2019
- 资助金额:
$ 54.97万 - 项目类别:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
使用 LVS dcapB 载体平台开发安全有效的类鼻疽疫苗
- 批准号:
9815937 - 财政年份:2019
- 资助金额:
$ 54.97万 - 项目类别:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
使用 LVS dcapB 载体平台开发安全有效的类鼻疽疫苗
- 批准号:
10159194 - 财政年份:2019
- 资助金额:
$ 54.97万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 54.97万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 54.97万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 54.97万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 54.97万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 54.97万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 54.97万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 54.97万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 54.97万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 54.97万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 54.97万 - 项目类别:
Continuing Grant














{{item.name}}会员




